Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study

A recent extensive analysis by Truveta Research has revealed that Eli Lilly And Co's LLY blockbuster diabetes drug Mounjaro (tirzepatide), proves more effective for weight loss in overweight or obese adults compared to Novo Nordisk A/S's NVO Ozempic (semaglutide). 

According to Truveta Research's real-world study, patients on Mounjaro demonstrated substantial weight loss percentages of 5%, 10%, and 15% compared to their counterparts on Ozempic over three months, six months, and a year. 

The study, examining health-care data from about 18,000 overweight or obese adults initiating either Mounjaro or Ozempic between May 2022 and September 2023, highlights Mounjaro's remarkable efficacy in weight reduction.

Within one year of starting treatment, 42.3% of those taking tirzepatide had lost at least 15% of their weight, compared with 19.3% among patients taking semaglutide, according to the study published on medRxiv.

81.8% of tirzepatide patients lost at least 5% of their weight compared to 64.6% on semaglutide, with 62.1% vs. 38.0% losing at least 10%.

After three months of treatment, patients on Mounjaro had lost an average of 2.3% more body weight than those taking Ozempic, the study also found. By six months, the difference had widened to 4.3%; by 12 months, the Mounjaro group had lost an average of 7.2% more weight.

Rates of gastrointestinal adverse events were similar between groups.

Price Action: LLY stock is down 0.10% at $590.95, and NVO stock is down 1.48% at $102.33 during the premarket session on the last check Tuesday.